Cargando…

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life

AIMS: Hyperkalaemia (HK) is common in heart failure (HF) patients, related to renal dysfunction and medical treatment. It limits medical therapy optimization, which impacts prognosis. New potassium (K) binders help control HK, allowing better medical management of HF. METHODS AND RESULTS: A retrospe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esteban‐Fernández, Alberto, Ortiz Cortés, Carolina, López‐Fernández, Silvia, Recio Mayoral, Alejandro, Camacho Jurado, Francisco Javier, Gómez Otero, Inés, Molina, María, Almenar Bonet, Luis, López‐Vilella, Raquel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715760/ https://www.ncbi.nlm.nih.gov/pubmed/35748119 http://dx.doi.org/10.1002/ehf2.13976

Ejemplares similares

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
por: Slawik, Jonathan, et al.
Publicado: (2020)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

A new area for the management of hyperkalaemia with potassium binders: clinical use in nephrology
por: Rossignol, Patrick
Publicado: (2019)

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments
por: Zannad, Faiez, et al.
Publicado: (2019)

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland
por: Ward, Thomas, et al.
Publicado: (2022)

Potassium homoeostasis and pathophysiology of hyperkalaemia
por: Kjeldsen, Keld Per, et al.
Publicado: (2019)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
por: Pitt, Bertram, et al.
Publicado: (2018)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
por: Ward, Thomas, et al.
Publicado: (2023)

Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program
por: Rossignol, Patrick, et al.
Publicado: (2021)

Pharmacodynamic effects of the K(+) binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats
por: Iyer, Sai Prasad N., et al.
Publicado: (2020)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
por: Bushinsky, David A, et al.
Publicado: (2015)

Gut Microbiota and Host Cometabolism Are Altered by Patiromer-Induced Changes in Serum and Stool Potassium
por: Gao, Bei, et al.
Publicado: (2020)

Long-term mortality and trajectory of potassium measurements following an episode of acute severe hyperkalaemia
por: Gorriz, José Luis, et al.
Publicado: (2021)

Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study
por: Rafique, Zubaid, et al.
Publicado: (2023)

Prevalence, Incidence, and Outcomes of Hyperkalaemia in Patients with Chronic Heart Failure and Reduced Ejection Fraction from a Spanish Multicentre Study: SPANIK-HF Design and Baseline Characteristics
por: Delgado-Jiménez, Juan F., et al.
Publicado: (2022)

Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN
por: Pitt, Bertram, et al.
Publicado: (2018)

Case report: Patiromer-induced hypercalcemia
por: Wiederkehr, Michael R., et al.
Publicado: (2019)

Management of hyperkalaemia in adults.
por: McVeigh, G.
Publicado: (2005)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
por: Pinnell, Derek, et al.
Publicado: (2022)

Assessing patiromer utilization and associated serum potassium changes in US veterans with prior sodium polystyrene sulfonate exposure
por: Patel, Shardool, et al.
Publicado: (2023)

Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs
por: Uijtendaal, Esther V., et al.
Publicado: (2011)

A Rare Case of Patiromer Induced Hypercalcemia
por: Kanduri, Swetha Rani, et al.
Publicado: (2021)

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia
por: Li, Lingyun, et al.
Publicado: (2016)

Comparative efficacy of patiromer and sodium polystyrene sulfonate on potassium levels in chronic haemodialysis patients: a randomized crossover trial
por: Jaques, David A, et al.
Publicado: (2022)

Severe hyperkalaemia: demographics and outcome
por: Phillips, B.M., et al.
Publicado: (2014)

Surreptitious hyperkalaemia and its complications
por: Morgenstern, Tilo, et al.
Publicado: (2009)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Can patiromer allow for intensified renin–angiotensin–aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD
por: Mårup, Frederik Husum, et al.
Publicado: (2022)

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)

Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect
por: Bhattarai, Shreeyukta, et al.
Publicado: (2019)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

COVID-19 Infection in Heart Transplants in Pre- and Postvaccination Periods
por: Donoso Trenado, Víctor, et al.
Publicado: (2022)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Hyperkalaemia: aetiology, epidemiology, and clinical significance
por: Tromp, Jasper, et al.
Publicado: (2019)

Suxamethonium-chloride: Hyperkalaemia: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_r8r7s8u13fhm3d56nrbtbbntsb